Results 101 to 110 of about 20,878 (216)
Supplementary Appendix from Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
, 2023 Steven Coutré, Richard R. Furman, Ian W. Flinn, Jan A. Burger, Kristie A. Blum, Jeff P. Sharman, Jeffrey A. Jones, William G. Wierda, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Anh Tran, Cathy Zhou, Elizabeth Bilotti, Danelle F. James, John C. Byrd, Susan O’Brien +16 moreopenalex +1 more sourceDevelopment and validation of an UHPLC-MS/MS method for simultaneous quantification of ibrutinib and its dihydrodiol-metabolite in human cerebrospinal fluid
, 2018 David Beauvais, J.-F. Goossens, E. Boyle, Ben Allal, Thierry Lafont, Étienne Chatelut, Charles Herbaux, Franck Morschhauser, Stéphanie Genay, Pascal Odou, Cécile Danel +10 moreopenalex +2 more sourcesA PHASE I STUDY OF IBRUTINIB COMBINED WITH RITUXIMAB, IFOSFAMIDE, CARBOPLATIN, AND ETOPOSIDE IN PATIENTS WITH RELAPSED OR PRIMARY REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA [PDF]
, 2017 Craig S. Sauter, Matthew J. Matasar, Heiko Schöder, Pamela Drullinsky, John F. Gerecitano, Anita Kumar, Ariela Noy, M. Lia Palomba, C. Portlock, David J. Straus, Andrew D. Zelenetz, S.S. McCall, Shoshana T. Miller, Amanda I. Courtien, Anas Younes, Craig H. Moskowitz +15 moreopenalex +1 more sourceArrhythmogenic cardiomyopathy mimicking cardiac amyloidosis with Waldenström macroglobulinaemia: A diagnostic challenge
ESC Heart Failure, Volume 12, Issue 6, Page 4555-4565, December 2025.Lianyue Ma, Lin Chen, Jiaqi Li, Qian Wang, Xiangjuan Liu, Xiaoling Liu, Yun Zhang, Mei Ni +7 morewiley +1 more sourceThe Direction of Modern Therapies in Waldenström Macroglobulinaemia
Journal of Cellular and Molecular Medicine, Volume 29, Issue 24, December 2025.ABSTRACT
Waldenström macroglobulinaemia (WM) is a rare lymphoplasmacytic disease that is hallmarked by B‐cell infiltration of the bone marrow, an overexpression of IgM class antibodies and an activating mutation of MYD88 (L265P). The therapeutic options for WM patients include a combination of Rituximab (anti‐CD20 monoclonal antibody) and chemotherapy, Stephen Blackmore, Sherine Elsawa, Omid Tavana +2 morewiley +1 more sourceThe role of time to first progression and fitness status in elderly patients with mantle cell lymphoma: Results from the ELDERLY MANTLE‐FIRST study
HemaSphere, Volume 9, Issue 12, December 2025.Francesca Maria Quaglia, Annalisa Arcari, Lucia Morello, Luigi Marcheselli, Alessandra Tucci, Chiara Pagani, Valentina Bozzoli, Greta Scapinello, Francesco Piazza, Vittorio Ruggero Zilioli, Cristina Muzi, Benedetta Puccini, Benedetta Sordi, Maria Chiara Tisi, Nicolò Rampi, Alessia Castellino, Sara Veronica Usai, Jari Paternoster, Emanuele Cencini, Simone Ferrero, Chiara Consoli, Marco Basso, Elisa Lucchini, Elsa Pennese, Maria Elena Nizzoli, Michele Spina, Luca Pezzullo, Maria Stella De Candia, Rita Tavarozzi, Mauro Krampera, Carlo Visco +30 morewiley +1 more sourceSingle-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia [PDF]
, 2019 Gilles Salles, Emmanuel Bachy, Lukáš Smolej, Martin Šimkovič, Lucile Baseggio, Anna Panovská, Hervé Besson, Nollaig Healy, Jamie Garside, Wafae Iraqi, Joris Diels, Corinna Pick-Lauer, Martin Špaček, Renata Urbanová, Daniel Lysák, Ruben Hermans, Jessica Lundbom, Evelyne Callet‐Bauchu, Michael Doubek +18 moreopenalex +1 more source
